A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizumab in adult subjects with advanced solid tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509335-60-00

Acronym

M21-404

Enrollment

177

Registered

2024-07-11

Start date

2023-02-23

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors including (but not limited to), and renal cell carcinoma (RCC), colorectal cancer (CRC), gastric/gastroesophageal junction adenocarcinoma (GEA), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC)

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France, Germany, Poland, Spain

Outcome results